Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

1. de Botton, S.
2. Montesinos, P.
3. Schuh, A.C.
4. Papayannidis, C.
5. Vyas, P.
6. Wei, A.H.
7. Ommen, H.
8. Semochkin, S.
9. Kim, H.-J.
10. Larson, R.A.
11. Koprivnikar, J.
12. Frankfurt, O.
13. Thol, F.
14. Chromik, J.
15. Byrne, J.
16. Pigneux, A.
17. Thomas, X.
18. Salamero, O.
19. Vidriales, M.B.
20. Doronin, V.
21. Döhner, H.
22. Fathi, A.T.
23. Laille, E.
24. Yu, X.
25. Hasan, M.
26. Martin-Regueira, P.
27. DiNardo, C.D.
28. Show all authors +

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1182/BLOOD.2021014901 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

•